HomeProductsBioactive CompoundsProtein Kinase Targetsc-KitMotesanib
Chemical structure of CAS 453562-69-1

Motesanib

CAS No.453562-69-1
MDL No.MFCD10567689
MFC22H23N5O
MW373.50
InChI KeyRAHBGWKEPAQNFF-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Motesanib is a pyridinecarboxamide.

CAS No.453562-69-1
Product NameMotesanib

Biological Targets

PDGFRB·PDGFRA·KIT·RET·FLT1·

Associated Conditions

breast cancer·lung cancer·breast neoplasm·malignant colon neoplasm·rectum cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.

Cancer chemotherapy and pharmacology • Vol. 65, Issue 5 • 2010
PMID: 19690858PMC: PMC2824121DOI: 10.1007/s00280-009-1103-9

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • Vol. 27, Issue 23 • 2009
PMID: 19564535DOI: 10.1200/JCO.2008.18.7815

In vitro metabolism of the novel, highly selective oral angiogenesis inhibitor motesanib diphosphate in preclinical species and in humans.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 37, Issue 7 • 2009
PMID: 19372226DOI: 10.1124/dmd.108.025742

Targeting RET for thyroid cancer therapy.

Biochemical pharmacology • Vol. 77, Issue 3 • 2009
PMID: 19028457DOI: 10.1016/j.bcp.2008.10.033

Documentation

Similar Products